Skip to main content
. Author manuscript; available in PMC: 2015 Apr 23.
Published in final edited form as: Proc SPIE Int Soc Opt Eng. 2009 Feb 18;7164:71640B. doi: 10.1117/12.809897

Figure 6.

Figure 6

A comparison of prostate coverage for PDT dose in the heterogeneous prostate among three conditions: ignoring clinic PS drug distribution (dashed line), with clinical PS drug distribution (solid line) and with linear PS drug distribution (dotted line). The source strengths are listed in Table 1.